These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 10320627)

  • 1. Preemptive pharmacologic intervention in radiation-induced salivary dysfunction.
    Taylor SE; Miller EG
    Proc Soc Exp Biol Med; 1999 May; 221(1):14-26. PubMed ID: 10320627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathophysiology and management of radiation-induced xerostomia.
    Berk LB; Shivnani AT; Small W
    J Support Oncol; 2005; 3(3):191-200. PubMed ID: 15915820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
    Thorstad WL; Chao KS; Haughey B
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):8-12. PubMed ID: 15726516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early to late sparing of radiation damage to the parotid gland by adrenergic and muscarinic receptor agonists.
    Coppes RP; Zeilstra LJ; Kampinga HH; Konings AW
    Br J Cancer; 2001 Sep; 85(7):1055-63. PubMed ID: 11592779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New approaches to preventing xerostomia.
    J Support Oncol; 2006 Feb; 4(2):87-8. PubMed ID: 16499130
    [No Abstract]   [Full Text] [Related]  

  • 6. Salivary gland sparing in the treatment of head and neck cancer.
    Scrimger R
    Expert Rev Anticancer Ther; 2011 Sep; 11(9):1437-48. PubMed ID: 21929317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical management of salivary gland hypofunction and xerostomia in head-and-neck cancer patients: successes and barriers.
    Vissink A; Mitchell JB; Baum BJ; Limesand KH; Jensen SB; Fox PC; Elting LS; Langendijk JA; Coppes RP; Reyland ME
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):983-91. PubMed ID: 20970030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiation-induced xerostomia: pathophysiology, clinical course and supportive treatment.
    Guchelaar HJ; Vermes A; Meerwaldt JH
    Support Care Cancer; 1997 Jul; 5(4):281-8. PubMed ID: 9257424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients.
    de Castro G; Federico MH
    Curr Opin Oncol; 2006 May; 18(3):266-70. PubMed ID: 16552239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural history and prevention of radiation injury.
    O'Connell AC
    Adv Dent Res; 2000 Dec; 14():57-61. PubMed ID: 11842925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiotherapy-induced salivary dysfunction.
    Ship JA; Hu K
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):29-36. PubMed ID: 15726520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation-induced xerostomia in patients with head and neck cancer: a literature review.
    Dirix P; Nuyts S; Van den Bogaert W
    Cancer; 2006 Dec; 107(11):2525-34. PubMed ID: 17078052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buccal drug delivery technologies for patient-centred treatment of radiation-induced xerostomia (dry mouth).
    Malallah OS; Garcia CMA; Proctor GB; Forbes B; Royall PG
    Int J Pharm; 2018 Apr; 541(1-2):157-166. PubMed ID: 29425763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic pilocarpine for treatment of xerostomia.
    Berk L
    Expert Opin Drug Metab Toxicol; 2008 Oct; 4(10):1333-40. PubMed ID: 18798702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 clinical study of cell therapy with effective-mononuclear cells (E-MNC) for radiogenic xerostomia (first-in-human study) (FIH study on E-MNC therapy for radiogenic xerostomia).
    Sumita Y; Iwamoto N; Seki M; Yoshida T; Honma R; Iwatake M; Ohba S; Takashi I; Hotokezaka Y; Harada H; Kuroshima S; Nagai K; Asahara T; Atsushi Kawakam I; Asahina I
    Medicine (Baltimore); 2020 Jun; 99(26):e20788. PubMed ID: 32590759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Manifestations and treatment of xerostomia and associated oral effects secondary to head and neck radiation therapy.
    Garg AK; Malo M
    J Am Dent Assoc; 1997 Aug; 128(8):1128-33. PubMed ID: 9260423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of oral pilocarpine in xerostomia and Sjögren's syndrome.
    Nusair S; Rubinow A
    Semin Arthritis Rheum; 1999 Jun; 28(6):360-7. PubMed ID: 10406404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current status of prevention and management of radiation-induced xerostomia].
    Ma DY; Qiu WL; Zhang CP
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2010 Feb; 45(2):121-3. PubMed ID: 20368009
    [No Abstract]   [Full Text] [Related]  

  • 19. Protection of salivary function by intensity-modulated radiation therapy in patients with head and neck cancer.
    Chao KS
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):20-5. PubMed ID: 11917280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot study of subcutaneous amifostine in patients undergoing postoperative intensity modulated radiation therapy for head and neck cancer: preliminary data.
    Thorstad WL; Haughey B; Chao KS
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):96-100. PubMed ID: 14727249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.